BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Gyre Therapeutics (GYRE)Gyre TherapeuticsCommercial

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed

Related news

KYTXKyverna Therapeutics2026-06-22 12:00 EST

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

CUECue Biopharma Inc2026-06-02 20:05 EST

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

KYTXKyverna Therapeutics2026-07-27 12:00 EST

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

HCWBHCW Biologics2026-05-27 11:45 EST

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

INMBINmune Bio2026-07-20 11:00 EST

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

AVTXAvalo Therapeutics2026-06-23 11:00 EST

Avalo Therapeutics Appoints Ron Philip to Board of Directors

XFORX4 Pharmaceuticals2026-07-01 11:00 EST

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

KYMRKymera2026-06-08 20:01 EST

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

View all latest news

Gyre Therapeutics

Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic...

Recent company news

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYREGyre Therapeutics2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GYREGyre Therapeutics2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

GYREGyre Therapeutics2026-05-04 12:48 EST

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Stock data

Close
6.40 USD
Market cap
539.48M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States